{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:05:29Z","timestamp":1780445129904,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-41577-1","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:47:10Z","timestamp":1775908030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study"],"prefix":"10.1038","volume":"16","author":[{"given":"Xutai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjian","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"3","key":"41577_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"41577_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"41577_CR3","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"41577_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello, R. J. et al. Prostate cancer. Nat. Rev. Dis. Primers. 7 (1), 9 (2021).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"41577_CR5","doi-asserted-by":"crossref","unstructured":"Fenton, J. J. et al. Prostate-specific antigen\u2013based screening for prostate cancer. JAMA 319(18). (2018).","DOI":"10.1001\/jama.2018.3712"},{"issue":"18","key":"41577_CR6","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.ejca.2011.06.055","volume":"47","author":"TP Kilpel\u00e4inen","year":"2011","unstructured":"Kilpel\u00e4inen, T. P. et al. False-positive screening results in the European randomized study of screening for prostate cancer. Eur. J. Cancer (Oxford England: 1990). 47 (18), 2698\u20132705 (2011).","journal-title":"Eur. J. Cancer (Oxford England: 1990)"},{"issue":"2","key":"41577_CR7","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bju.12368","volume":"113","author":"PF Pinsky","year":"2014","unstructured":"Pinsky, P. F., Parnes, H. L. & Andriole, G. Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial. BJU Int. 113 (2), 254\u2013259 (2014).","journal-title":"BJU Int."},{"issue":"9959","key":"41577_CR8","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schroder","year":"2014","unstructured":"Schroder, F. H. et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 384 (9959), 2027\u20132035 (2014).","journal-title":"Lancet"},{"key":"41577_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1471-2296-3-19","volume":"3","author":"RM Hoffman","year":"2002","unstructured":"Hoffman, R. M., Gilliland, F. D., Adams-Cameron, M., Hunt, W. C. & Key, C. R. Prostate-specific antigen testing accuracy in community practice. BMC Fam. Pract. 3, 19 (2002).","journal-title":"BMC Fam. Pract."},{"issue":"4","key":"41577_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.diii.2020.01.014","volume":"101","author":"C Han","year":"2020","unstructured":"Han, C. et al. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4\u223c10ng\/mL: Biparametric versus multiparametric MRI. Diagn. Interv. Imaging. 101 (4), 235\u2013244 (2020).","journal-title":"Diagn. Interv. Imaging"},{"issue":"2","key":"41577_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2214\/AJR.17.18946","volume":"211","author":"XK Niu","year":"2018","unstructured":"Niu, X. K. et al. Diagnostic performance of biparametric MRI for detection of prostate cancer: A systematic review and meta-analysis. AJR Am. J. Roentgenol. 211 (2), 369\u2013378 (2018).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1","key":"41577_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/ua.ua_22_22","volume":"15","author":"MA Arafa","year":"2023","unstructured":"Arafa, M. A. et al. False-positive magnetic resonance imaging prostate cancer correlates and clinical implications. Urol. Ann. 15 (1), 54\u201359 (2023).","journal-title":"Urol. Ann"},{"issue":"2","key":"41577_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 79 (2), 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"issue":"11","key":"41577_CR14","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/jama.2014.2085","volume":"311","author":"JH Hayes","year":"2014","unstructured":"Hayes, J. H. & Barry, M. J. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 311 (11), 1143\u20131149 (2014).","journal-title":"JAMA"},{"issue":"9","key":"41577_CR15","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/sj.bjc.6605648","volume":"102","author":"RC Macefield","year":"2010","unstructured":"Macefield, R. C. et al. Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br. J. Cancer. 102 (9), 1335\u20131340 (2010).","journal-title":"Br. J. Cancer"},{"issue":"1","key":"41577_CR16","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1186\/s40001-025-03369-7","volume":"30","author":"H Zhou","year":"2025","unstructured":"Zhou, H. et al. Evaluation of the diagnostic performance of YiDiXie\u2122 tests in urothelial carcinoma. Eur. J. Med. Res. 30 (1), 1113 (2025).","journal-title":"Eur. J. Med. Res."},{"key":"41577_CR17","doi-asserted-by":"publisher","unstructured":"Sun, C. et al. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie\u2122-S, YiDiXie\u2122-SS and YiDiXie\u2122-SSS. medRxiv 2024:2024.2003.2011.24303683. https:\/\/doi.org\/10.1101\/2024.03.11.24303683","DOI":"10.1101\/2024.03.11.24303683"},{"issue":"2","key":"41577_CR18","first-page":"93","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin, M. B. et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J. Clin. 67 (2), 93\u201399 (2017).","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"41577_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/sim.1783","volume":"23","author":"SA Julious","year":"2004","unstructured":"Julious, S. A. Sample sizes for clinical trials with normal data. Stat. Med. 23 (12), 1921\u20131986 (2004).","journal-title":"Stat. Med."},{"issue":"3","key":"41577_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0004-9514(14)60228-2","volume":"48","author":"M Davidson","year":"2002","unstructured":"Davidson, M. The interpretation of diagnostic test: a primer for physiotherapists. Aust. J. Physiother. 48 (3), 227\u2013232 (2002).","journal-title":"Aust. J. Physiother."},{"issue":"13","key":"41577_CR21","doi-asserted-by":"publisher","first-page":"5261","DOI":"10.7314\/APJCP.2015.16.13.5261","volume":"16","author":"CC Chang","year":"2015","unstructured":"Chang, C. C. et al. Diagnostic Role of Serum Free-to-Total Prostate Specific Antigen (PSA) Ratio in Prostate Cancer with Serum Total Concentration of PSA below 4 ng\/mL. Asian Pac. J. Cancer Prev. APJCP. 16 (13), 5261\u20135264 (2015).","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"3","key":"41577_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3329\/bmrcb.v38i3.14333","volume":"38","author":"MM Rashid","year":"2012","unstructured":"Rashid, M. M. et al. Efficacy of lower cut off value of serum prostate specific antigen in diagnosis of prostate cancer. Bangladesh Med. Res. Counc. Bull. 38 (3), 90\u201393 (2012).","journal-title":"Bangladesh Med. Res. Counc. Bull."},{"issue":"9","key":"41577_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/BF02599596","volume":"11","author":"JB Meigs","year":"1996","unstructured":"Meigs, J. B., Barry, M. J., Oesterling, J. E. & Jacobsen, S. J. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J. Gen. Intern. Med. 11 (9), 505\u2013512 (1996).","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"41577_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-021-02230-y","volume":"20","author":"SWD Merriel","year":"2022","unstructured":"Merriel, S. W. D. et al. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients. BMC Med. 20 (1), 54 (2022).","journal-title":"BMC Med."},{"key":"41577_CR25","doi-asserted-by":"publisher","first-page":"b3537","DOI":"10.1136\/bmj.b3537","volume":"339","author":"B Holmstr\u00f6m","year":"2009","unstructured":"Holmstr\u00f6m, B. et al. Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (Clinical Res. ed). 339, b3537 (2009).","journal-title":"BMJ (Clinical Res. ed)"},{"issue":"2","key":"41577_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11547-017-0814-y","volume":"123","author":"E Faiella","year":"2018","unstructured":"Faiella, E. et al. Analysis of histological findings obtained combining US\/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative. Radiol. Med. 123 (2), 143\u2013152 (2018).","journal-title":"Radiol. Med."},{"issue":"3","key":"41577_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jmri.22075","volume":"31","author":"K Kitajima","year":"2010","unstructured":"Kitajima, K. et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J. Magn. Reson. Imaging JMRI. 31 (3), 625\u2013631 (2010).","journal-title":"J. Magn. Reson. Imaging: JMRI"},{"issue":"6","key":"41577_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1464-410X.2012.11329.x","volume":"112","author":"S Hori","year":"2013","unstructured":"Hori, S., Blanchet, J. S. & McLoughlin, J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 112 (6), 717\u2013728 (2013).","journal-title":"BJU Int."},{"issue":"8","key":"41577_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1515\/cclm-2022-0354","volume":"60","author":"L Agnello","year":"2022","unstructured":"Agnello, L. et al. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis. Clin. Chem. Lab. Med. 60 (8), 1261\u20131277 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"issue":"1","key":"41577_CR30","doi-asserted-by":"publisher","first-page":"15193","DOI":"10.1038\/s41598-022-19460-6","volume":"12","author":"J Freds\u00f8e","year":"2022","unstructured":"Freds\u00f8e, J. et al. Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine. Sci. Rep. 12 (1), 15193 (2022).","journal-title":"Sci. Rep."},{"issue":"7","key":"41577_CR31","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1515\/cclm-2015-0876","volume":"54","author":"V Pecoraro","year":"2016","unstructured":"Pecoraro, V., Roli, L., Plebani, M. & Trenti, T. Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review. Clin. Chem. Lab. Med. 54 (7), 1123\u20131132 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"issue":"8","key":"41577_CR32","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41416-022-01881-9","volume":"127","author":"B Trujillo","year":"2022","unstructured":"Trujillo, B., Wu, A., Wetterskog, D. & Attard, G. Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. Br. J. Cancer. 127 (8), 1394\u20131402 (2022).","journal-title":"Br. J. Cancer"},{"issue":"6","key":"41577_CR33","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.eururo.2020.12.037","volume":"79","author":"I Casanova-Salas","year":"2021","unstructured":"Casanova-Salas, I. et al. Quantitative and qualitative analysis of blood-based liquid biopsies to inform clinical decision-making in prostate cancer. Eur. Urol. 79 (6), 762\u2013771 (2021).","journal-title":"Eur. Urol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41577-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41577-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:35:56Z","timestamp":1780443356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41577-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41577"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41577-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of this study was approved by the Ethics Committee of Peking University Shenzhen Hospital. All participants recruited in our study provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17079"}}